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Abstract
Background: Immunofluorescence and virus culture are the main methods used to diagnose acute
respiratory virus infections. Diagnosing these infections using nucleic acid amplification presents technical
challenges, one of which is facilitating the different optimal annealing temperatures needed for each virus.
To overcome this problem we developed a diagnostic molecular strip which combined a generic nested
touchdown protocol with in-house primer master-mixes that could recognise 12 common respiratory
viruses.
Results: Over an 18 month period a total of 222 specimens were tested by both immunofluorescence
and the molecular strip. The specimens came from 103 males (median age 3.5 y), 80 females (median age
9 y) and 5 quality assurance scheme specimens. Viruses were recovered from a number of specimen types
including broncho-alveolar lavage, nasopharyngeal secretions, sputa, post-mortem lung tissue and
combined throat and nasal swabs. Viral detection by IF was poor in sputa and respiratory swabs. A total
of 99 viruses were detected in the study from 79 patients and 4 quality control specimens: 31 by
immunofluorescence and 99 using the molecular strip. The strip consistently out-performed
immunofluorescence with no loss of diagnostic specificity.
Conclusions:  The touchdown protocol with pre-dispensed primer master-mixes was suitable for
replacing virus culture for the diagnosis of respiratory viruses which were negative by
immunofluorescence. Results by immunofluorescence were available after an average of 4–12 hours while
molecular strip results were available within 24 hours, considerably faster than viral culture. The combined
strip and touchdown protocol proved to be a convenient and reliable method of testing for multiple
viruses in a routine setting.
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Background
Acute respiratory tract infections are major causes of mor-
bidity and mortality. In 2000, lower respiratory tract
infections were globally the number one infectious cause
of disability adjusted life-years [1]. The commonest respi-
ratory viruses that cause acute upper and lower respiratory
tract infections and which are routinely tested for in most
virus diagnostic laboratories are: influenza A virus (FLA);
influenza B virus (FLB); respiratory syncytial virus (RSV);
parainfluenza virus type 1 (PF1); parainfluenza virus type
2 (PF2); parainfluenza virus type 3 (PF3) and adenovirus
(ADV). Additionally, human rhinoviruses (HRV) and
coronavirus 229E (CoV-229E) are also linked to acute res-
piratory infection but less commonly included in labora-
tory reports; human metapneumovirus (hMPV) is not yet
part of most United Kingdom virus laboratory test reper-
toires (personal feed-back from the United Kingdom Clin-
ical Virology Network).
As part of service development it was necessary to provide
an alternative to virus culture for testing immunofluores-
cence negative respiratory specimens. Historically and
indeed currently immunofluorescence [2] and virus cul-
ture [3,4] are the main methods used to diagnose acute
respiratory virus infections. Culture is accepted as more
sensitive than immunofluorescence but slower and there-
fore less useful for direct patient management decisions.
Using a standard culture technique [4] for the culture of
respiratory viruses our median reporting times for culture
positive and culture negative specimens were 6 days
(based on 407 specimens) and 7 days (based on 2159
specimens) respectively; virus identification by this tech-
nique required the use of monoclonal antibody staining
of the cell monolayer in addition to observation for viral
cytopathic effect. We therefore wished to develop a test
capable of reporting on immunofluorescence negative
specimens within a 24 hour period.
Increasingly however, the sensitivity of nucleic acid ampli-
fication techniques for diagnosis has become recognised
[5-10]. However widespread concerns about contamina-
tion issues [11,12] and perceived cost [13] have slowed
their widespread adoption. An added problem for acute
respiratory tract infections is the relatively large number of
viruses that need to be accounted for, a problem which
presents specific technical challenges.
One such challenge is the different optimal annealing
temperatures of the primer sets for each prospective virus
target. The ABI PRISM 7000 real-time facility from
Applied Biosystems addresses this by using bundled soft-
ware to design primer/probe combinations that use a
common amplification protocol. However this approach
is compromised by the inability of software to allow for
target heterogeneity. In addition it does not allow users to
adopt clinically validated primer sets from the literature.
To address these problems we adopted an alternative
approach through the development of a generic touch-
down amplification protocol. Touchdown protocols
involve a pre-designed stepped reduction in the annealing
temperature used for primer-to-template binding, which
introduces a competitive advantage for specific base-pair
priming over non-specific priming [14]. A detailed knowl-
edge of the optimum annealing temperature is therefore
not required. The study protocol was empirically con-
structed and proved robust when applied to a large range
of respiratory viral and bacterial targets, without compro-
mising individual test sensitivity. It was designed for use
with in-house primer master-mixes that recognise 12
common respiratory viruses.
Before deciding on the layout of the molecular strip, as
described in the methods, we undertook a wide range of
preliminary validation steps for each primer set. The com-
plexity of the strip makes it impossible to fully evaluate
using the classical approach of applying an individual
gold standard to each virus type. Classically this approach
works well where a single target is under investigation
[15]. However although the strip is putatively designed to
identify 12 viruses, the actual number of individual types
targeted is over one hundred and sixty because of the
inclusion of generic primer sets for HRV [16] and ADV
[17] respectively. The classical approach is further com-
pounded for viruses (a) that cannot be grown or grown
easily; (b) for which commercial IF sera are not available;
(c) for which specimen panels are not available. We there-
fore adopted a phased validation, culminating in the
present study. Sensitivity was ascribed by undertaking
copy number determination on cloned targets and these
ranged form 6 × 103 copies per ml for human rhinovirus
type 1b to 4.2 × 103 copies/ml for RSV-A. Specificity was
ascribed through reproducibility, i.e. specimens which
were repeatedly positive, following our standard clinical
reporting algorithm [6], were regarded as true positives; a
similar approach was recently described for hMPV [18]. In
addition amplicon sequencing was used as an initial spe-
cificity check. The primers sets were tested on clinical res-
piratory specimens arising from a number of ethically
approved studies. These included respiratory specimens
from patients: (a) with chronic obstructive pulmonary
disease; (b) with acute asthma; (c) on assisted ventilation
in intensive care. They were also tested on respiratory
specimens collected as part of an influenza spotter pro-
gram as well as on laboratory specimens of known virus
reactivity.
To test the feasibility of its routine use we needed to clin-
ically validate its performance in a routine setting onBMC Microbiology 2004, 4:41 http://www.biomedcentral.com/1471-2180/4/41
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specimens tested in parallel with our standard immun-
ofluorescence protocol for the diagnosis of acute virus res-
piratory infections. Although the routine
immunofluoresence panel lacked capacity for the detec-
tion of rhinoviruses, human metapneumovirus and CoV-
229E, these were included on the strip for clinical reasons
during the period of the study. These findings and their
implications are reported.
Results
Patients and specimens
A total of 99 viruses were detected in 84/222 specimens
from a total of 79/183 patients and 4/5 National External
Quality Assurance Scheme (NEQAS) controls; immun-
ofluorescence did not detect the parainfluenza virus type
2 virus in one of the NEQAS specimens. Viruses were
detected in all of the specimen types processed. The
molecular strip detected virus in: 16/36 (44.4%) broncho-
alveolar lavages, 62/120 (51.6%) nasopharyngeal secre-
tions, 11/35 (31.4%) sputa and 10/31 (32.2%) combined
throat and nasal swabs. Immunofluorescence detected
virus in: 6/36 (16.6%) broncho-alveolar lavages, 23/120
(19.1%) nasopharyngeal secretions, 1/35 (2.8%) sputa
and 1/31 (3.2%) combined throat and nasal swabs.
The median age of male and female patients where virus
was detected was 3 y (range 2 weeks – 79 years) and 4 y (5
weeks – 81 years) respectively. Sixteen viruses were
detected in 14/27 (51.8%) specimens, confirming a respi-
ratory virus in 12 out of 24 (50%) patients investigated in
general practice. Seventy-nine viruses were detected in 70/
191 (36.6%) specimens, confirming a respiratory virus in
67 out of 159 (42.1%) patients investigated in hospital.
Of the 16 viruses detected in specimens from the commu-
nity, PCR detected all 16 in contrast to a single identifica-
tion, influenza A (H3), by immunofluorescence.
Nested PCR
PCR identified one or more viruses in specimens from 84
of the 183 patients and the 4 NEQAS positive specimens,
detecting a total of 99 viruses as shown in Table 1. The
viruses detected were: influenza A (H3) virus (17); influ-
enza A (H1) virus (4); influenza B virus (2); human rhi-
novirus (39); adenovirus (22); parainfluenza virus type 2
(1); parainfluenza virus type 3 (10); respiratory syncytial
virus type A (2); respiratory syncytial virus type B (2);. No
parainfluenza virus type 1, coronavirus 229E or human
metapneumovirus were detected.
Dual infections were detected in 11/79 (13.9%) patients.
The dual infections were: influenza A (H3) and adenovi-
rus (4); influenza A (H3) virus and rhinovirus (2); influ-
enza A (H1) and adenovirus (1); adenovirus and
rhinovirus (3); respiratory syncytial virus type B and rhi-
novirus (1).
Nine patients had more than one specimen taken on the
same day in which a virus was detected in at least one
specimen by PCR. For 5 of the patients the same virus was
detected in each of the 2 specimens. The viruses identified
were rhinovirus (3), adenovirus (1) and parainfluenza
type 3 (1); the latter was also immunofluorescence posi-
tive. In 2 cases a rhinovirus was detected in only one of the
specimens. As part of a separate rhinovirus validation pro-
tocol one of these specimens was subjected to retesting
coupled with limited sequencing of the 5' non-coding
region amplicon which confirmed the presence of a rhi-
novirus sequence. Additionally, premature twin boys
admitted to intensive care on the same day with severe
bronchiolitis, both had evidence of acute rhinovirus infec-
tion by PCR. Limited sequencing of the 5' non-coding
region of these viruses as part of the rhinovirus validation
protocol confirmed the presence of an identical sequence
of rhinovirus in both specimens.
Table 1: Viruses detected by the molecular strip and immunofluorescence.
Virus Molecular Strip Immunofluorescence
Influenza A Virus 21* 15
Influenza B Virus 2 1
Human Rhinovirus 39 Not Tested
Adenovirus 22 3
Parainfluenza Virus Type 2 1 0
Parainfluenza Virus Type 3 10 8
Respiratory Syncytial Virus 4§ 4
Total Positive 99 31
Total Tested 222 222
* Included 17 influenza A H3 and 4 influenza A H1.
§ Included 2 respectively of respiratory syncytial virus type A and type B.BMC Microbiology 2004, 4:41 http://www.biomedcentral.com/1471-2180/4/41
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Immunofluorescence
Immunofluorescence identified a virus in specimens from
28 of the 183 patients and 3/4 NEQAS positive specimens
(16.4%), detecting a total of 31 viruses as shown in Table
1. The viruses detected were: influenza A virus (15); influ-
enza B virus (1); parainfluenza virus type 3 (8); respira-
tory syncytial virus (4); adenovirus (3). No parainfluenza
virus types 1 or 2 were detected including a NEQAS mock
parainfluenza virus type 2 infection which was recorded
as negative. No dual infections were detected. One patient
had 2 specimens taken on the same day in which the same
virus, parainfluenza type 3, was detected.
Discussion
Although touchdown PCR has been used successfully to
help overcome some of the uncertainties associated with
the thermal amplification of microbial nucleic acid targets
[19-22], its use in this study has extended its role further
and in so doing brought closer the goal of undertaking
molecular diagnostics in a routine setting. Previously its
main impact has been seen where multiplexing [23,24] or
degenerate primers have been needed [25-27] and where
the problems of choosing correct annealing temperatures
are at their most difficult.
In this study the large number of targets is the main prob-
lem encountered. Using an empirical approach a series of
amplification steps linked to a stepped reduction in
annealing temperature from 55°C to 46°C was con-
structed. This proved extremely resilient when used with a
wide range of primer sets and included the apparent
anomaly of putting adenovirus through an initial reverse
transcription step to stream line all of the targets on to a
single strip; we have previously reported this approach for
testing group F adenovirus alongside norovirus, astrovirus
and rotavirus [28]. The touchdown surprisingly out-per-
formed individual amplification protocols optimised for
annealing temperature and thus proved suitable for use
on the diverse range of respiratory viruses addressed in the
study.
Where multiple viral targets are sought in clinical practice,
we believe that it is only feasible to correlate the perform-
ance of the new assay in a head-to-head comparison with
that already in routine use. Unfortunately for many clini-
cal laboratories there is an elusion of testing for a wider
range of viruses than is the case, by the inoculation of cell
lines with a theoretical ability to grow the respective
viruses. The annual reports of most clinical laboratories of
one of the commonest human respiratory viruses, human
rhinovirus, is an example of this; using the touchdown
protocol we now report approximately 450 HRV infec-
tions per annum. The under reporting of adenovirus by
standard methods [17] and the paucity of hMPV report-
ing, further underlines this assertion.
The ability to simultaneously validate the performance of
multiple molecular primer sets in a routine clinical setting
is a major accomplishment of the current methodological
approach. The results demonstrated that a range of prim-
ers from both the medical literature and from in-house
development could be amplified with a single generic
touchdown protocol. It therefore confirmed the feasibility
of directly incorporating primer sets into a standard oper-
ating procedure without the necessity for the individual
optimisation of cycling parameters. As such the study
results should facilitate primer selection and formal criti-
cal evaluation as here described. As an example of this
enhanced flexibility we have recently replaced the primer
sets for influenza A H1 and H3 (with respective copy
number sensitivities of 8 × 103 and 2 × 103 copies per ml)
with a generic matrix set (copy number sensitivity of 1 ×
103 copies per ml).
The use of strips containing pre-dispensed mastermixes
facilitates their use in a routine setting where laboratory
personnel have only to thaw the strip and add the speci-
men extract. We make and aliquot for routine use a large
range of multi-reaction mastermixes which are repeatedly
subjected to freeze-thaw cycles as required on a daily
basis. Provided the mixes are handled on ice, they remain
extremely stable, over many months if so required. How-
ever the strip is designed for a single use only and thus
only goes through a single freeze-thaw cycle. Mix stability
is not a problem and the single positive control is used
only to confirm that the touchdown amplification cycle
has run successfully.
Because the technique of using nested amplification fol-
lowed by running agarose gel electrophoresis is relatively
cumbersome, it was important to evaluate how the com-
plete protocol, inclusive of report generation, would per-
form when introduced into a routine line-managed
diagnostic setting. Over the 18 months of the study the
technique fitted in well to the demands of routine service.
Central to this was the use of pre-dispensed and quality
checked primer master-mixes which allowed the molecu-
lar strip to be adapted for use in a routine laboratory. The
study confirmed that a broad based molecular approach
was feasible as an alternative to virus culture to support
immunofluorescence in the diagnosis of respiratory
viruses. The overall superior performance of the strip and
the missed NEQAS specimen by immunofluorescence
underlines the need for a more sensitive back-up for neg-
ative specimens.
While nested protocols must be regarded as a pragmatic,
interim solution until perfected single round systems are
available, the format of the strip reduces the concern most
attached to nested formats, i.e. false positive results. In our
experience there is little evidence to supportBMC Microbiology 2004, 4:41 http://www.biomedcentral.com/1471-2180/4/41
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contamination arising from environmental sources and
that the two major points of contamination in a nested
system are (a) cross-contamination during manual extrac-
tion and (b) contamination of second round adjacent
wells with product from a first round positive amplifica-
tion. The use of the QIAGEN BioRobot for the extraction
of all specimens reduced the former while the nature of
the strip prevents the latter, since all the wells have sepa-
rate mixes (Table 2). With both nested and non-nested
assays the most critical requirements for reliable results
are the use of well trained, appropriately skilled and
knowledgeable staff, operating in a managed environ-
ment. As with any service, test performance must stand up
to both external and internal quality assurance and in this
regard we welcome the new respiratory quality control
panel soon to be made available from Quality Control for
Molecular Diagnostics (QCMD), Glasgow.
The results obtained were very encouraging. Although the
strip was constructed to detect a wider range of viruses
than immunofluorescence, over the period of validation it
almost doubled (59 versus 31) the number of viruses that
could have been detected by immunofluorescence,
including a positive NEQAS specimen which was missed
by immunofluorescence. Of this group of viruses the
detection of adenovirus showed the most dramatic
increase, an observation we have also previously made in
a separate study [17] and which we continue to see both
in routine respiratory specimens and in a number of res-
piratory studies. Similar to HRV viruses we believe these
common infections are underdiagnosed by the standard
techniques of immunofluorescence and culture. They are
the second commonest virus, after HRV, that we observe
in mixed infections and it is self-evident that these addi-
tional infections are at a level below the detection thresh-
olds of standard methods. Their clinical significance when
detected at these lower copy numbers remains to be
determined.
As mentioned in the introduction a factor which often
impacts negatively on a laboratory's decision to use
molecular diagnostics is one of cost. It is worth consider-
ing that no matter which assay is chosen for use, it will
attract the same overheads needed to provide the infra-
structure of a laboratory set-up i.e. building, utilities, staff
and equipment. In this regard there are no cheap tests and
to use reagent costs as the sole factor in determining
which assay to use is somewhat perverse. While the rea-
gent costs of the strip are higher that commercial immun-
ofluorescence reagents by a factor of 3, including
extraction, this would undoubtedly narrow if immunoflu-
orescence were capable of closing the pathogen gaps that
currently exist e.g. HRV, hMPV. Currently using this
approach, we have been able to replace both immunoflu-
orescence and viral culture and this ability makes molecu-
lar diagnostics a more cost effective method for
diagnosing viral infections. Taking into account the supe-
rior range, sensitivity, ability to quantify and speed of
molecular techniques it is incredible how little they are
used in routine laboratories. With the advent of SARS and
the threat of avian influenza, this deficit is now beginning
to disturb health care planners at the highest level.
Because specimen sampling was not contiguous seasonal
peaks were not detected, accounting for the small num-
bers of respiratory syncytial virus detected and the lack of
detection of human metapneumoviruses, parainfluenza
virus type 1 and coronavirus 229E; subsequent (unpub-
lished) data from the routine use of the molecular strip
support an important role for human metapneumovirus
in acute respiratory infections and the sporadic nature of
infections caused by parainfluenza type 1 and coronavirus
229E.
Several interesting observations need highlighting. First,
for immunofluorescence to perform reliably it was essen-
tial that a good nasopharyngeal specimen was available.
The use of throat and/or nasal swabs with immunofluo-
rescence alone is inappropriate. Second, immunofluores-
cence was very poor at detecting viruses from patients in
the community, again almost certainly because of the uni-
versal use of swabs in that setting. Third, the rapid results
of immunofluorescence were complemented by the
touchdown protocol which can report definitive results
within 24 hours, considerably faster than culture. Fourth,
the molecular strip was better at detecting multiple infec-
tions. Even allowing for the inability of immunofluores-
cence to detect rhinoviruses, it should have detected the
mixed adenovirus and influenza virus infections.
Although immunofluorescence is capable of diagnosing
dual infections, its routine use along with culture proba-
bly grossly underestimates their prevalence. The most
plausible explanation is that the molecular technique
detects infections where one of the viruses is below the
Table 2: Template for position of primer master-mixes on the 
molecular strip.
Well Number Virus
1 Parainfluenza Virus Types 1,2,3
2 Human metapneumovirus
3 Influenza A H1 & oronavirus 229E
4 Influenza A H3 & Human Rhinovirus
5I n f l u e n z a  B  V i r u s
6 Respiratory Syncytial Virus Types A & B
7 Adenovirus
8 Positive ControlBMC Microbiology 2004, 4:41 http://www.biomedcentral.com/1471-2180/4/41
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detection threshold of immunofluorescence. These low
level viruses are either just starting or more likely reaching
the end of an infectious episode (latency is less likely) and
this raises the previously unaddressed question of their
role in viral respiratory pathogenesis. Fifth, the extent of
rhinovirus infections was very significant. Their clinical
significance ranged from acting as a definitive respiratory
pathogen to a less certain role when acting as the most fre-
quently detected co-pathogen in mixed infections.
Conclusions
In conclusion the use of the touchdown protocol with
pre-dispensed and quality checked primer master-mixes
was suitable for replacing virus culture for the diagnosis of
respiratory viruses for immunofluorescence negative spec-
imens. Immunofluorescence results were available after
an average of 4–12 hours while molecular strip results
were available within 24 hours, considerably faster than
viral culture. The combined strip and touchdown protocol
is a convenient and reliable method of testing for multiple
viruses in a routine setting. Its generic nature makes it
especially useful for introducing test repertoire modifica-
tions e.g. incorporating primers for the newly identified
coronaviruses SARS-CoV and HCoV-NL63.
Methods
Patients and specimens
A total of 222 specimens were included in the validation
between January 2002 and June 2003, including 14 from
an influenza surveillance scheme. The specimens were
collected from 183 patients including: 103 male, median
age 3.5 y (7 m – 84 y); 80 female patients, median age 9 y
(7 m – 84 y); both male and female ages were skewed
towards the lower age ranges, and 5 national external
quality assurance scheme (NEQAS) specimens (4 positive,
1 negative). One hundred and fifty-nine patients were in
hospital and 24 were in the community at the time of
sampling. Specimens tested consisted of a wide range of
specimens including: broncho-alveolar lavage (36),
nasopharyngeal secretions (120), sputum (35) and com-
bined throat and nasal swabs (31).
Immunofluorescence
Nasopharyngeal secretions, broncho-alveolar lavage and
sputum specimens were received in dry sterile containers
at ambient temperature. Upon receipt they were re-sus-
pended in 2 ml of virus transport medium (VTM) consist-
ing of phosphate buffered saline pH 7.1, bovine serum
albumin 7.5 µg/ml, penicillin G sodium 1000 units/ml,
streptomycin sulphate 1000 µg/ml and amphotericin B
2.5 µg/ml. Throat and nasal swabs were received in 2 ml
of VTM and vortexed on arrival to release cells attached to
the fibres of the swab. An aliquot of 410 µl was taken off
for extraction after which the specimens were centrifuged
at 2600 g for 5 min and the resulting cell deposits air-dried
on glass multi-well slides and fixed in acetone prior to
testing. Immunofluorescence was set up on the respiratory
specimens using commercial reagents according to the
manufacturer's instructions, and was able to detect: influ-
enza A, influenza B, respiratory syncytial virus, adenovi-
rus, parainfluenza type 1, parainfluenza type 2 and
parainfluenza type 3 (Dako diagnostics, Ely, UK).
Specimen extraction
A volume of 200 µl of the respiratory specimen suspen-
sion was extracted on a QIAGEN BioRobot 9604 using the
Blood and Body Fluid Vacuum Protocol of the QIAamp
DNA Blood Kit (Qiagen Ltd., Crawley, England, U.K).
This protocol allows the co-extraction of both RNA and
DNA simultaneously.
Nested PCR
Simultaneous amplification of all targets was facilitated
by using a standard 8 well multi-well PCR strip to which
all mixes were pre-dispensed and stored frozen; this for-
mat is referred to in the paper as the "respiratory strip"
because of the respiratory nature of the targets. The respi-
ratory strip targeted the following 12 common respiratory
viruses: influenza A (H3), influenza A (H1), influenza B,
respiratory syncytial virus type A, respiratory syncytial
virus type B, adenovirus, coronavirus 229E, parainfluenza
virus type 1, parainfluenza virus type 2, parainfluenza
virus type 3, human rhinovirus and human metapneumo-
virus. The final configuration of the single and multiplex
primer mixes in the 8 well strip are shown in Table 2. The
primer sets used were taken mainly from published stud-
ies [16,29-31] but also included primer sets validated in-
house after modification or de-novo design, including
those for influenza A (H1), influenza A (H3) and the
generic adenovirus primers [17]. The primers, gene targets
and expected product sizes following amplification are
shown in Table 3.
Each primer master-mix was made-up and titrated against
a known positive control before being aliquoted and dis-
pensed into its respective well of the 8-well microtube
strip. The strips were stored frozen at -20°C until used. A
positive control was also aliquoted and stored separately
at -20°C until used. For the duration of the study the pos-
itive control was the cloned target of parainfluenza virus
type 1; a negative control was not deemed necessary.
First round volumes were made-up in Access RT-PCR
buffer (Promega, Southampton, England, U.K) and in the
final 10 µl volume contained the following reagent
amounts: 1.5 mM MgSO4, 1 unit AMV reverse
transcriptase, 1 unit Tfl DNA polymerase, 0.2 mM each
deoxynucleoside triphosphate (dATP, dCTP, dGTP, dTTP)
and 1 µM outer primers.BMC Microbiology 2004, 4:41 http://www.biomedcentral.com/1471-2180/4/41
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Second round volumes were made-up in Taq Buffer B
(Promega) and in the final 10 µl volume contained the
following final amounts: 10 mM Tris-HCl (pH 9.0), 3.5
mM MgCl2, 50 mM KCl, 0.1% Triton X-100, 0.2 mM of
each deoxynucleoside triphosphate (dATP, dCTP, dGTP,
dTTP), 0.25 units of Taq DNA polymerase (Promega) and
0.2 µM inner primers.
First round amplification was performed on 2 µl of extract
added to 8 µl of first round primer master-mix per well.
Second round amplification was performed on 0.2 µl of
Table 3: Primer sequences, gene targets and expected product sizes for viruses on the molecular strip.
Name Sequence (5' to 3') Gene Target 1st/2nd Size (bp)
PF1 1A CCT TAA ATT CAG ATA TGT AT HN1 14 7 8
PF1 1B GAT AAA TAA TTA TTG ATA CG
PF1 1C CCG GTA ATT TCT CAT ACC TAT G 2 317
PF1 1D CCT TGG AGC CGA GTT GTT AAG
PF2 1A AAC AAT CTG CTG CAG CAT TT HN1 15 0 8
PF2 1B ATG TCA GAC AAT GGG CAA AT
PF2 1C CCA TTT ACC TAA GTG ATG GAA T 2 204
PF2 1D GCC CTG TTG TAT TTG GAA GAG A
PF3 2A CTTG TAA ACT CAG ACT TGG TA HN1 14 7 8
PF3 2B TTT AAG CCC TTG TCA ACA AC
PF3 2C ACT CCC AAA GTT GAT GAA AGA T 2 103
PF3 2D TAA ATC TTG TTG TTG AGA TTG
hMPV 1A GCG GCA ATT TTC AGA CAA CG Fusion 1 696
hMPV 1B ACA TGC TGT TCG CCT TCA AC
hMPV 1C CAG CAG CAG GAA TCA ATG TT 2 288
hMPV 1D TCG CCT TCA ACT TTG CTT AG
CoV229E 1A GGT ACT CCT AAG CCT TCT C G Nucleocapsid 1 450
CoV229E 1B TGC ACT AGG GTT AAG AAG AGG
CoV229E 1C TTT GGA AGT GCA GGT GTT GTG G 2 100
CoV229E 1D GAC TAT CAA ACA GCA TAG CAG C
ENT 2A TCC TCC GGC CCC TGA ATG 5' Non-coding 1 120
ENT 2B GAA ACA CGG ACA CCC AAA GTA
ENT 1C GGC CCC TGA ATG CGG CTA AT 2 90
HRV 1B GGT CCC RTC CCG CAA TT
FLA 3A (H1)2 GAA ATT TGC TAT GGC TGA C Haemagglutinin 1 482
FLA 3B (H1)2 ATA TTT TGG GCA CTC TCC TAT
FLA 3C (H1)2 GTC TCT GTA GTG TCT TCA CAT TAT 2 197
FLA 3D (H1)2 CCG GAC CCA AAC CCT CTA CTC
FLB 1A GTG ACT GGT GTG ATA CCA CT Haemagglutinin 1 900
FLB 1B TGT TTT CAC CCA TAT TGG GC
FLB 1C CAT TTT GCA AAT CTC AAA GG 2 767
FLB 1D TGG AGG CAA TCT GCT TCA CC
FLA 2C (H3)2 AGC AAA GCT TTC AGC AAC TG Haemagglutinin 1 591
FLA 2D (H3)2 GCT TCC ATT TGG AGT GAT GC-3
FLA 2E (H3)2 AGT GCT GAA CGT GAC TAT GC 2 149
FLA 2F (H3)2 TTT GCT GGC TTC TCT TGG T
RSV 2A GTC TTA CAG CCG TGA TTA GG Nucleoprotein 1 838
RSV 2B GGG CTT TCT TTG GTT ACT TC
RSVA 2C GAT GTT ACG GTG GGG AGT CT 2 334
RSVA 2D GTA CAC TGT AGT TAA TCA CA
RSVB 2C AAT GCT AAG ATG GGG AGTTC 2 183
RSVB 2D GAA ATT GAG TTA ATG ACA GC
ADV 2A2 GCCGCAGTGGTCTTACATGCACATC Hexon 1 301
ADV 2B2 CAGCACGCCGCGGATGTCAAAGT
ADV 2C32 GACGCCTCGGAGTACCTSWSYCC 2 185
ADV 2DD2 TACGAGTACGTGGTGTCCTCKCGRTC
1 HN = Haemagglutinin-neuraminidase gene; 2 Primer sets designed for this study. N.B. 1 = 1st round primer set, 2 = 2nd round primer set; ENT 2A 
2B, 1C, HRV 1B primer set = Rhinovirus.BMC Microbiology 2004, 4:41 http://www.biomedcentral.com/1471-2180/4/41
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the first round reaction added to 9.8 µl of second round
primer master-mix per well; a multi-channel pipette facil-
itated the transfer of the 8 volumes in one step. The posi-
tive control was run on the eighth well of each strip. The
second round products were run on ethidium bromide
stained 2% agarose gels and photographed. Specimens
were reported positive when respectively the correct size
bands and the positive control bands were present.
Touchdown amplification protocol
Amplification was carried out on a range of thermal
cyclers including the Applied Biosystems GeneAmp 2400
and 9700 series and a DNA Engine Tetrad PTC 225 (MJ
Research, USA). The first and second round amplification
protocols consisted of 36 identical cycles with the excep-
tion that (a) a reverse transcription step of 48°C-10 min
preceded the first round and (b) a hot-start preceded the
second round by transferring the strip directly from ice to
a thermal cycler held at 94°C. The touchdown protocol
consisted of 6 steps as follows: (a) initial denaturation
(94°C-2 min); (b) 3 cycles of denaturation (94°C-30 s),
annealing (55°C-30 s) and extension (72°C-30 s); (c) 3
cycles of denaturation (94°C-30 s), annealing (52°C-30
s) and extension (72°C-30 s); (d) 20 cycles of
denaturation (94°C-30 s), annealing (49°C-30 s) and
extension (72°C-30 s); (e) 10 cycles of denaturation
(94°C-30 s), annealing (46°C-30 s) and extension (72°C-
30 s); (f) 72°C for 5 mins.
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